KDR and neoplasm: These agents represent mechanistically distinct but complementary therapeutic strategies that inhibit epithelial growth factor signaling (FGFR2b), disrupt tumor-restricted tight junctions (CLDN18.2), and block pathological angiogenesis (VEGFR2).